Bayer AG 2011 AR2
The report highlights Bayer's successful fiscal year 2011, during which the company achieved its financial and innovation targets, with Group sales increasing by 4.1% to €36.5 billion. Key operational milestones included the commercialization of new pharmaceutical products like Xarelto and the expansion of the BioScience business. In terms of sustainability, the company defined new targets for 2015, including a commitment to reduce specific greenhouse gas emissions by 35% by 2020. Additionally, Bayer successfully reduced its absolute greenhouse gas emissions by 4.2% in 2011 despite a 5% increase in production volume.
Company: Bayer AG
Sector: Manufacturing
Country: Germany
Year: 2011
Type: AR2
Pages: 265
Back to company
Bayer AG
Annual Report
The report highlights Bayer's successful fiscal year 2011, during which the company achieved its financial and innovation targets, with Group sales increasing by 4.1% to €36.5 billion. Key operational milestones included the commercialization of new pharmaceutical products like Xarelto and the expansion of the BioScience business. In terms of sustainability, the company defined new targets for 2015, including a commitment to reduce specific greenhouse gas emissions by 35% by 2020. Additionally, Bayer successfully reduced its absolute greenhouse gas emissions by 4.2% in 2011 despite a 5% increase in production volume.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Women in Management
Employees